Introduction {#Sec1}
============

Complicated skin and soft tissue infections (cSSTIs) are among the most common infections treated in the hospital setting \[[@CR1], [@CR2]\]. They represent the more extreme end of the clinical spectrum of SSTIs \[[@CR3]\] as they typically involve deep soft tissue and occur in patients with underlying disease, often requiring intravenous (IV) antibiotic therapy and/or surgical intervention \[[@CR2]\]. As a result, their treatment incurs high healthcare costs. cSSTIs frequently complicate clinically significant medical conditions such as peripheral arterial disease, diabetes mellitus or renal insufficiency and can also cause complications in immunocompromised hosts \[[@CR4]\].

Gram-positive pathogens are the predominant cause of cSSTIs. *Staphylococcus aureus* (*S. aureus*) was found to be the most frequently occurring pathogen among hospitalized SSTI patients on a global scale in the SENTRY Antimicrobial Surveillance Program \[[@CR5]\], and in a large observational study with 1995 cSSTIs patients hospitalized in Europe \[[@CR1]\]. Antibiotic resistance in isolates from SSTIs has increased significantly over time \[[@CR6]--[@CR10]\], but the emergence of meticillin-resistant *S. aureus* (MRSA) is recognized as the greatest resistance concern \[[@CR5]\], as it complicates the treatment of cSSTIs, limits therapeutic options and impacts treatment outcomes.

Systemic infections with MRSA are associated with a higher mortality rate, a longer length of stay (LOS) in hospital, and greater healthcare costs than non-MRSA infections \[[@CR11]\].

In Greece, where antimicrobial drug resistance rates remain high \[[@CR12]\], MRSA prevalence reaches 40%, which is among the highest in Europe \[[@CR13]\] and comparable to figures reported for the USA \[[@CR14]\]. The increase in MRSA, in part, reflects the changing epidemiology of soft tissue infections as a consequence of the recent dramatic increase in the incidence of community acquired MRSA (CA-MRSA), the pathogen most commonly isolated from SSTIs in many locations in the US \[[@CR15]\]. CA-MRSA strains are distinct from hospital-acquired strains, cause mainly skin and soft tissue infections (ranging in severity from furuncles to necrotizing fasciitis), and are associated with the production of virulence factors like the Panton Valentine Leukocidin (PVL) toxin, which may further complicate treatment \[[@CR16]\]. In Europe, the prevalence of infections due to CA-MRSA appear to vary across the continent, with Greece reporting one of the highest rates (30%) of *S. aureus* infection in outpatients compared to 6--18% in other Western European countries \[[@CR16], [@CR17]\].

Successful management of cSSTI involves prompt recognition, timely surgical debridement or drainage, resuscitation if required and appropriate antibiotic therapy \[[@CR3]\]. Treatment for MRSA-related cSSTIs may include either IV or per os (PO) pharmaceutical treatment for 7--14 days and in most cases hospitalization is required. Vancomycin (VANCO) has historically been the standard of care for MRSA infections, but adverse effects, the need for IV access and growing resistance, tend to limit its use \[[@CR7]\]. Newer antimicrobials such as daptomycin (DAPTO), linezolid (LINE) and telavancin have shown comparable efficacy to VANCO and are recommended in international guidelines \[[@CR18]\].

Use of proper antimicrobial treatment is an illustrative example of the tradeoffs between increased pharmaceutical spending and decreased resource use costs. Given the scarcity of economic and human healthcare resources and the fact that the cost of available antimicrobial treatments varies, the purpose of the present study was to identify healthcare resource use and cSSTI total inpatient costs, along with other associated costs for different antibiotic treatments in the Greek hospital setting. A secondary objective was to perform a budget impact analysis for the inpatient treatment of MRSA-cSSTIs.

Methods {#Sec2}
=======

Model Overview {#Sec3}
--------------

A previously published economic model \[[@CR19]\] was adapted for the Greek hospital setting, to examine the healthcare resource use and associated economic impact of different management approaches for MRSA-cSSTIs. The model was developed using Microsoft Excel and Visual Basic, and was based on a decision tree for the management of hospitalized patients with MRSA-cSSTIs (Fig. [1](#Fig1){ref-type="fig"}), which simulated costs and outcomes for the duration of hospitalization according to different therapeutic scenarios.Fig. 1General model outline for the first-line management of hospitalized MRSA-cSSTI patients. *cSSTI* complicated skin and soft tissue infections, *MRSA* meticillin-resistant *Staphylococcus aureus*

The time horizon for the decision tree was a maximum of 14 days including inpatient empirical and first-line treatment where all patients remained hospitalized.

The most common first-line treatment pathways in the management of MRSA-cSSTIs were elicited from a panel of seven local experts (infectious disease specialists), i.e., DAPTO, LINE, teicoplanin (TEICO), tigecycline (TIGE), and VANCO. Cotrimoxazole or tetracyclines were not considered as, according to the expert panel, these are most commonly used for outpatients with mild SSTIs and are not preferred in the management of hospitalized patients with MRSA confirmed cSSTIs.

Efficacy rates for LINE and VANCO were assumed to be equal in terms of clinical success for the length of treatment (89.8%)---weighted average between LINE clinical success rate (219 out of 239 treated cases) and VANCO clinical success rate (193 out of 220 treated cases), as reported by the non-inferiority study of Itani et al. \[[@CR20]\]. For the purpose of the analysis and for simplicity reasons, DAPTO, TIGE and TEICO were also assumed to present equal efficacy rates. Regardless of efficacy assumptions, the adverse event failure rate was calculated as (1−success rate) × 0.33, assuming 1/3 of treatment failures are due to adverse events and 2/3 are due to lack of efficacy \[[@CR11]\]. Patients not cured after receiving first-line antibiotic treatment or who presented with adverse events were assumed to be cured after receiving second-line therapy. The set of patients who discontinued or failed therapy required additional hospitalization days as per the input of the expert panel. As this study was conducted from a hospital perspective, treatment continuation with second-line agents in the outpatient setting was not incorporated into the analysis.

Model Input Data {#Sec4}
----------------

Treatment pathways and associated resource use relevant to the local setting were obtained from an expert panel, made up of seven infectious disease specialists. To be included as a member of the expert panel, each participant was required to have long-term, recognized professional experience in treating patients with MRSA-cSSTIs. The panel was varied in terms of level and setting of healthcare provision, i.e., university clinics, NHS hospitals and community clinics, as well as geographic distribution across the Greek mainland.

Data were gathered using a series of closed type questions pertaining to the current management of a "typical" MRSA-cSSTI patient treated in Greece. Resources included hospitalization, hospital procedures, medical visits, laboratory/diagnostic tests and medication associated with MRSA-cSSTIs and its complications. The mean values from all expert responses gathered were used in the study. In view of the lack of relevant data from Greek hospitals, the panel of experts provided information on estimated antibacterial use. The expert panel also provided the information on additional healthcare resource requirements, collectively indicating that drug failures and drug discontinuations due to adverse events resulted in an additional seven and five hospital days, respectively. Moreover, an average per patient-per day hospitalization cost for MRSA-cSSTIs was estimated based on cSSTI diagnosis and diagnosis-related group (DRG) mapping. This was deemed appropriate as several DRG codes were identified by the group of experts as being cSSTI relevant. Continuation of first-line treatment in the outpatient setting was not taken into consideration due to the fact that the study was conducted from a hospital perspective only.

The resource usage pattern for different treatments (as elicited by the expert panel) is reported in Table [1](#Tab1){ref-type="table"}. Unit costs for antibiotic agents and inpatient stays are reported in Table [2](#Tab2){ref-type="table"}.Table 1First-line treatment resource use according to expert panelResource usage^a^Mean values reported by the expert panelDAPTOLINETEICOTIGEVANCONo. of days of treatment^b^9.89.211.511.711.8No. of days in hospital^c^10.39.214.013.012.5No of days IV9.86.71211.711.8Average daily dose (mg)^d^4581,2005001332,000IV doses per day1.02.01.02.02.0No. of days oral0.02.50.00.00.0Oral doses per day0.02.00.00.00.0Additional no. of days in hospital due to AE55555Additional no. of days in hospital due to treatment failure77777*AE* adverse events, *DAPTO* daptomycin, *IV* intravenous, *LINE* linezolid, *TEICO* teicoplanin, *TIGE* tigecycline, *VANCO* vancomycin^a^Values are calculated as means of expert panel feedback^b^Excluding the treatment time prior to cultivation results^c^Time from hospital admission to discharge^d^Estimated for a 'typical' 75 kg patientTable 2Unit cost of inputsResourceInput costSource/assumptionInpatient cost per day€189.20Mean DRG cost for cSSTI, weighted according to expert panel, based on diagnosis \[[@CR21]\]Vancomycin IV 1 g (empiric---35%, first line)€8.92Cheapest generic selected \[[@CR22]\]Other IV empiric (daptomycin---26%, Linezolid---14%, teicoplanin---9%, Tigecycline---12%, clindamycin---4%)€33.89Average weighted daily cost according to usage % in the Greek hospital settingDaptomycin IV 500 mg€87.50\[[@CR22]\]Linezolid IV 600 mg€37.17\[[@CR22]\]Linezolid PO tab 600 mg€32.80\[[@CR22]\]Tigecycline IV 50 mg€37.10\[[@CR22]\]Teicoplanin IV 400 mg€18.41\[[@CR22]\]*DRG* diagnosis-related group, *IV* intravenous, *PO* per os (orally)

Model Outcomes {#Sec5}
--------------

Inpatient costs consisted of hospitalization, diagnostic/laboratory testing, physician visits and antibiotic medication. Cost calculations were based on the corresponding tariffs of all services as reported in the official price lists of the National Health System. Hospitalization costs were based upon the current DRG system \[[@CR21]\]. Prices for medication were obtained from the Official Price Bulletin \[[@CR22]\]. All costs are reported in Euros for the year 2013. The budget impact analysis employed increasing market share for the most cost-saving antibacterial agent over a 3-year period, over the remaining most commonly used antibacterial agents, whose usage was decreased proportionally. Finally, drug price erosion was not taken into account.

Compliance with Ethics Guidelines {#Sec6}
---------------------------------

This article does not contain any new studies with human or animal subjects performed by any of the authors.

Results {#Sec7}
=======

Resource Use Pattern {#Sec8}
--------------------

According to the expert panel, MRSA-cSSTI patients in Greece are 56.6% males and most of them are over 60 years of age (57.1%). Patients receive empirical treatment for 2.57 days on average, until a culture-based antibiotic was selected. The panel also concluded that side effects leading to treatment discontinuation resulting from (any) pharmaceutical treatment were reported for 25.7% of cSSTI-treated patients in the inpatient setting (adverse events failure rate). The average additional LOS due to complications related to pharmaceutical treatment was reported at 4.8 days. The weighted mean DRG reimbursement cost per hospitalization day for the inpatient management of MRSA-cSSTI infections was found to be 189.20 Euros. The proportion of population matching each DRG-cSSTI code was used as weights to calculate mean cost per hospitalization day for the total cSSTI population. The total annual inpatient cost associated with cSSTIs currently in Greece was estimated at €29,196,218.

According to Table [3](#Tab3){ref-type="table"}, the total per patient cost according to first-line agent was €2,457, €2,762, €2,850, €3,094 and €3,494 for LINE, VANCO, DAPTO, TEICO, and TIGE, respectively. LINE as first-line treatment yields the lowest total inpatient cost per patient (€2,457) calculated per treatment cycle. This is mostly attributed to the relatively low hospitalization cost per patient (€1,889).Table 3Cost per patient breakdownTreatment schedules (first line)Total mean inpatient cost/patient (including empiric) €^a^Total inpatient (pharmaceuticals and medical)PharmaceuticalsHospitalization costsAE management costsFirst-line failure costsLINE2,4575681,8895890VANCO2,7622492,5135890DAPTO2,8507532,0975890TEICO3,0943002,7965890TIGE3,4948862,6075890*AE* adverse events, *DAPTO* daptomycin, *LINE* linezolid, *TEICO* teicoplanin, *TIGE* tigecycline, *VANCO* vancomycin^a^Total mean cost per "typical" patient includes medical costs and antibiotic acquisition cost. Medical costs breakdown into cost per day of hospitalization, treatment failure and adverse event costs

The current use of the most common antibacterial agents in the management of cSSTIs, as identified by the expert panel, along with an estimated 3-year gradual increase of the cost-saving antibacterial is presented in Table [4](#Tab4){ref-type="table"}.Table 4Current and proposed antibacterial usage estimatesDAPTOLINETEICOTIGEVANCOCurrent cSSTIs usage estimate (%)^a^261991135Proposed usage estimate---year 1 (%)2323101034Proposed usage estimate---year 2 (%)1927101034Proposed usage estimate---year 3 (%)1830111130*cSSTI* complicated skin and soft tissue infection, *DAPTO* daptomycin, *LINE* linezolid, *TEICO* teicoplanin, *TIGE* tigecycline, *VANCO* vancomycin^a^According to expert panel. Teicoplanin and tigecycline estimates considered stable. Any variations are due to rounding up in order to result with assumed 100% share with the five treatment options

Table [5](#Tab5){ref-type="table"} summarizes the economic impact resulting by gradually increasing LINE use for the treatment of MRSA-cSSTIs from 19% (current baseline case scenario) to 23% (year 1), to 27% (year 2) and up to 30% (year 3). Previously conducted studies estimate that 10,287 MRSA-cSSTI patients are treated annually in Greek hospitals \[[@CR23], [@CR24]\]. Inputting these figures into the current study model results in potential savings of €193,291 (year 1), €354,798 (year 2) and €347,977 (year 3) compared to the current baseline case scenario, thus a potential saving of €896,065 could be made after 3 years.Table 5Budget impact analysis of the gradual increase of LINE usage in the treatment of meticillin-resistant *S. aureus* complicated skin and soft tissue infectionsCurrent costCost after 1 yearCost after 2 yearsCost after 3 yearsInpatient pharmaceuticals€5,305,213€5,220,891€5,145,002€5,262,737Difference−€84,322−€160,211−€42,476Inpatient medical€23,891,005€23,782,036€23,696,418€23,585,504Difference−€108,968−€194,586−€305,501Total budget impact€29,196,218€29,002,927€28,841,420€28,848,241Difference−€193,291−€354,798−€347,977

Sensitivity Analysis {#Sec9}
--------------------

A series of one-way sensitivity analyses was performed to test the robustness of outcomes and the impact of individual variables on the results. Table [6](#Tab6){ref-type="table"} \[[@CR25], [@CR26]\] summarizes the results. Parameters with the most significant influence on the results were LINE usage (expanded use led to increased savings), LOS of treatment, and efficacy (success rate) for comparators. Unit prices for LINE and healthcare resources had a lesser impact.Table 6Budget impact results of the univariate sensitivity analysesChange from baseline valueTotal 3-year budget impact for increased use of LINE (€000s)Baseline case scenario^a^−896.15% change in LINE use (rise to 24%)−398.515% change in LINE use (rise to 34%)−1,976.4Increase of LINE proportionally to all comparators−1,465.3Equal LOS assumed for all comparators (14 days)198.6Differentiated LOS as reported by Itani et al. \[[@CR20]\]^b^VANCO (mean 8.9 days)−359.8^c^LINE (mean 7.6 days)−1,893.6Differentiated efficacy (success rate of treatment) as reported by Itani et al. \[[@CR20]\]^b^VANCO (88%)−947.1LINE (92%)10% increase in the price of LINE−777.810% decrease in the price of LINE−1,006.110% increase in all medical costs−956.910% decrease in all medical costs−835.2Alternative in-hospital per diem cost, as reported by WHO (309.65€), adjusted for inflation \[[@CR25], [@CR26]\]^d^−1,284.1*DAPTO* daptomycin, *LINE* linezolid, *LOS* length of stay, *TEICO* teicoplanin, *TIGE* tigecycline, *VANCO* vancomycin, *WHO* World Health Association^a^LINE use for the treatment of MRSA-cSSTIs increased from 19% (current use) to 30% of cases during a 3-year period^b^Not assumed equal as in the baseline case scenario^c^Based on the same usage assumptions as in baseline case scenario^d^Converted from international dollars

Discussion {#Sec10}
==========

Treatment of cSSTIs due to MRSA has significant cost implications within the hospital setting, as a result of additional LOS and extensive use of appropriate healthcare resources. This study aimed to (a) map the costs associated with inpatient treatment of cSSTIs due to MRSA in Greece, and (b) to analyze costs associated with different antibacterial therapies and the potential budget impact of increasing the usage of the lowest cost agent.

For the baseline case scenario (depicting the current treatment scenario in Greece), LINE was shown to be the most cost-saving first-line antimicrobial agent compared to other treatment options. By extending the scope of its current use (from 19% of patients to a hypothetical 30%), the total (aggregate) budget impact was €896,065 over a 3-year period. Although LINE drug acquisition cost approximates the average cost of the remaining available treatments for cSSTI, its use may result in significantly reduced medical costs, namely hospitalization costs, compared to other selected antibiotic treatments. Using LOS data from a large phase IV study \[[@CR20]\] for the treatment of documented MRSA-cSSTIs, LINE's budget impact savings were further increased to €1,893,600 for the 3-year period (Table [6](#Tab6){ref-type="table"}). Clinical data demonstrates 100% bioavailability \[[@CR27]\] of the oral LINE formulation, thus allowing continuation of therapy in both the inpatient and outpatient setting when clinically appropriate and without dosage adjustment.

In addition to reducing LOS and healthcare costs, the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America Guidelines suggest that conversion from parenteral to oral therapy using antimicrobials with excellent bioavailability, when the patient's condition allows, can reduce complications that may arise as a result of IV access. An antimicrobial management program which outlines clinical criteria and guidelines for oral switch could play an important role in safeguarding the balance between incremental antimicrobial acquisition costs and the development of resistance at an institutional level \[[@CR28]\].

Hospitalization has been recognized within international literature as the main cost driver in the treatment of MRSA infections, comprising up to 81% of total treatment costs and making early discharge a reasonable target for savings \[[@CR29], [@CR30]\]. A recent retrospective chart review in 12 European countries \[[@CR26]\] has shown that by applying early discharge criteria in MRSA-cSSTIs more than one-third of hospitalized patients in usual clinical practice could be discharged from the hospital (37.9% overall and 41.1% for Greece with a mean ± SD potential LOS reduction of 6.2 ± 8.2 and 7.5 ± 10.6 days, respectively).

A treatment strategy that would focus on early discharge followed by outpatient parenteral treatment (OPAT) use or use of orally available antimicrobials could be of benefit. However, OPAT treatment is rather costly and is not commonly used in the Greek NHS setting \[[@CR31]\].

As with every study of this kind, the outcomes must be interpreted in light of a number of limitations. First of all, the study design assumes equal effectiveness among the different treatment schedules. This probably leads to conservative estimations, considering that data from a recent systematic meta-analysis of 14 studies of six antibiotics (*n* = 1,840) suggested differences in efficacy of different MRSA-cSSTI pharmaceutical treatments \[[@CR32]\], mostly in favor of LINE. The assumption that all patients are cured after receiving second-line treatment and that no patients died represents a simplification of reality. The majority of studies in cSSTIs do report high clinical success and very low mortality rates \[[@CR15]\] which are similar for patients treated with LINE or VANCO \[[@CR20]\], however, second-line efficacy data are lacking. All model assumptions were based on a previously published model \[[@CR19]\] and were considered reasonable by the panel of experts. Moreover, the option of outpatient oral and IV treatment continuation was not taken into consideration as this falls beyond the scope of the study (hospital setting). However, this could have a substantial impact on total cost of treatment \[[@CR33]\], especially from an overall healthcare system perspective. Recent evidence shows that the administration of antibacterial treatment administered on an outpatient basis can reduce per patient costs up to 30% \[[@CR19]\].

Another limitation to be considered is the lack of Greek-specific pharmaceutical use and MRSA-cSSTI prevalence data. The use of an expert panel approach implies a level of uncertainty with respect to the data acquisition process \[[@CR34]\]. Furthermore, results may not be fully transferable to other treatment settings, as significant variation exists in clinical practice \[[@CR31]\]. The actual magnitude of this uncertainty is very difficult to quantify. However, the multidisciplinary make-up of the team of experts and the consistency of estimations produced by expert panels in Greece, as reported by previous research \[[@CR35]\] enhance the robustness of results. Moreover, recently published data on patients' age and sex, mean LOS and IV use in Greece from a retrospective study in 12 European countries \[[@CR31]\] are consistent with the results of the expert panel.

In actual terms, the economic benefits of LINE are heavily based on its ability to reduce LOS and associated hospital costs. This was evident in the case where equal LOS was hypothesized for all comparators, which resulted in VANCO being the least costly choice. Newer agents have been shown to reduce LOS and thus may offset (partially or fully) the costs of medication.

Finally, the use of the recently introduced DRGs costing system leads to an underestimation of the relevant costs. This is because the current DRG price lists in Greece do not include staff costs. This is likely to result in an underestimation of the actual cost of treating cSSTIs due to MRSA, especially within the hospital setting. It has to be noted that the average hospitalization cost per day for cSSTIs based on the DRG reimbursement system was found to be approximately half the respective cost compared to recently published literature in the Greek setting \[[@CR31]\] and the World Health Organization for inpatient cost per day (309.65 adjusted for inflation in 2012) \[[@CR25], [@CR26]\]. Furthermore, as with most pharmacoeconomic studies, drug acquisition costs used in the cost calculations lack consideration for price variation over time.

Notwithstanding its limitations, this study is an illustrative example of the importance of global hospital budget, where higher drug acquisition costs would be offset by the marked reduction in hospital and fixed costs due to early discharge.

Conclusion {#Sec11}
==========

According to current clinical practice, as depicted by the panel of experts in the present study, LINE is associated with the lowest total costs in the management of the "typical" MRSA-cSSTI patient. The lower costs for patients treated with LINE can be attributed to a switch to oral therapy and earlier hospital discharge. International experience shows that early discharge, when certain criteria are met, can reduce healthcare costs without compromising quality of care. In light of considerable hospital budget constraints, the development of hospital strategies to facilitate early discharge of patients, for example by introducing clinical criteria and guidelines for switching to oral treatments for MRSA-cSSTIs, could result in substantial savings for the Greek global hospital budget.
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